Teva’s undisclosed big product launch could be—and probably is—Lipitor. I.e. Teva could have a cut a deal with Ranbaxy to utilize Ranbaxy’s 180 days of H-W exclusivity, which is much too valuable an asset to waste.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”